NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
- Conditions
- Osteoarthritis, Knee
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1464
- Registration Number
- NCT00366938
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, E. Hanover, New Jersey, United States
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
- Conditions
- Knee Osteoarthritis
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1684
- Registration Number
- NCT00367315
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 41
- Registration Number
- NCT00367393
- Locations
- 🇩🇪
Novartis, Novartis, Germany
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2007-07-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 296
- Registration Number
- NCT00367094
- Locations
- 🇨🇳
Novartis, Beijing, China
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
- Conditions
- Constipation
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 670
- Registration Number
- NCT00365820
- Locations
- 🇺🇸
Novartis Pharmaceutical Corporation, East Hanover, New Jersey, United States
🇺🇸Investigative Site, Seattle, Washington, United States
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 500
- Registration Number
- NCT00366002
- Locations
- 🇺🇸
Investigative Site, Milwaukee, Wisconsin, United States
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
- Conditions
- Hypertension
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 198
- Registration Number
- NCT00360178
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1083
- Registration Number
- NCT00355134
- Locations
- 🇺🇸
University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects
- Conditions
- Influenza
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 125
- Registration Number
- NCT00354016
- Locations
- 🇩🇪
Betriebsarztlicher Dienst, Universitat Marburg, Robert-Koch-Str, 5,, Marburg, Germany
🇩🇪Werksarztzentrum Herborn, Westerwaldstr 36,, Herborn, Germany
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 571
- Registration Number
- NCT00353912
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States